Role of the MHC2TA gene in autoimmune diseases

Annals of the Rheumatic Diseases

Volumn 66, Issue 3, 2007, Pages 325-329

  Martínez, Alfonso ^a   Sánchez Lopez, Marta ^a   Varadé, Jezabel ^a   Mas, Ana ^a   Martín, M Carmen ^a   De Las Heras, Virginia ^a   Arroyo, Rafael ^a   Mendoza, Juan Luis ^a   Díaz Rubio, Manuel ^a   Fernández Gutiérrez, Benjamín ^a   De La Concha, Emilio G ^a   Urcelay, Elena ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENTERITIS; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MHC2TA GENE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANS-ACTIVATORS;

EID: 34147218691     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059428     Document Type: Article

References (56)

1. Friese MA, Jones EY, Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol 2005;26:559-61.
2. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005;5:793-806.
3. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 2004;34:1513-25, .
4. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002;109(Suppl):S21-33.
5. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997;16:2851-60.
6. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001;19:331-73.
7. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-12.
8. Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998;95:10746- 50.
9. MocKay K, Eyre S, Myerscough A, Milicic A, Barton A, Laval S, et al. Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum 2002;46:632-9.
10. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003;48:906-16.
11. John S, Shephard N, Liu G, Zeggini E, Cao M, Chen W, et al. Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am J Hum Genet 2004;75:54-64.
12. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
13. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-10.
14. Reich D, Patterson N, De Jager PL, McDonald GJ, Waliszewska A, Tandon A, et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet 2005;37:1113-18.
15. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-67.
16. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005;435:590-7.
17. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-6.
18. Godde R, Rohde K, Becker C, Toliat MR, Entz P, Suk A, et al. Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10,000 SNPs on DNA chips. J Mol Med 2005;83:486-94.
19. Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-8.
20. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991;38:1-15.
21. Harton JA, Linhoff MW, Zhang J, Ting JP. Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 2002;169:4088-93.
22. Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006;6:183-95.
23. Nimchuk Z, Eulgem T, Holt BF IIIrd, Dangl JL. Recognition and response in the plant immune system. Annu Rev Genet 2003;37:579- 609.
24. Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 2004;103:2809-15.
25. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
26. Hugof JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
27. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S, et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000;178:148-65.
28. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005;37:486-94.
29. Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet 2006;33:59-61.
30. Yazdani-Biuki B, Brickmann K, Wohlfahrt K, Mueller T, Marz W, Renner W, et al. The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients. Arthritis Res Ther 2006;8:R97.
31. Toyoda H, Wang SJ, Yang HY, Redford A, Magalong D, Tyan D, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
32. Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999;65:1647-55.
33. Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Scambler P, et al. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet 2001;9:627-33.
34. van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004;13:763-70.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
37. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9.
38. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
39. Koizumi K, Okamoto H, Iikuni N, Nakamura T, Kawamoto M, Momohara S, et al. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus. Ann Rheum Dis 2005;64:947-50.
40. Ghaderi M, Gambelunghe G, Tortoioli C, Brozzetti A, Jatta K, Gharizadeh B, et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J Clin Endocrinol Metab 2006;91:4107-11.
41. Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). Genes Immun 2002;3:34-7.
42. Heldt C, Listing J, Sozeri O, Blasing F, Frischbutter S, Muller B. Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis. Arthritis Rheum 2003;48:2779-87.
43. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci U S A 1998;95:5779-84.
44. Wekerle H, Sun D, Oropeza-Wekerle RL, Meyermann R. Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol 1987;132:43-57.
45. Neumann H. Control of glial immune function by neurons. Glia 2001;36:191-9.
46. Zeinstra E, Wilczak N, Streefland C, De Keyser J. Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules. Neuroreport 2000;11:89-91.
47. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-46.
48. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
49. Rasmussen HB, Kelly MA, Clausen J. Genetic susceptibility to multiple sclerosis: detection of polymorphic nucleotides and an intron in the 3′ untranslated region of the major histocompatibility complex class II transactivator gene. Hum Immunol 2001;62:371-7.
50. Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, et al. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 2002;169: 6720-32.
51. Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 2002;168:4173-83.
52. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
53. Menge T, Hartung HP, Stuve O. Statins - a cure-all for the brain? Nat Rev Neurosci 2005;6:325-31.
54. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 2006;54:393-407.
55. Kuipers HF, van den Elsen PJ. Statins and control of MHC2TA gene transcription. Nat Med 2005;11:365-6; author reply 66-7.
56. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.